Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Disparities in the practice of precision medicine

Nadeem Bilani • 8 Dec 2021
SABCS 2021
Breast Cancer

Nadeem Bilani, MD, Mount Sinai Morningside, New York, NY, discusses multi-gene testing in early-stage, HR+/HER2- breast cancer as evaluated in a National Cancer Database retrospective analysis. Dr Bilani highlights the importance of improving access to innovative, diagnostic and prognostic tools, among black and underinsured patients, as well as those treated in community practices.This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Nadeem Bilani

0:54
Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasis
Nadeem Bilani • 4 Jun 2023
0:53
Prognostic trials for 21-gene OncotypeDX in HR+/HER2- breast cancer with micrometastases
Nadeem Bilani • 4 Jun 2023
2:14
Survival in premenopausal HR+/HER2- breast cancer with micro-metastasis and 21-gene score
Nadeem Bilani • 4 Jun 2023
0:54
Do premenopausal patients with breast cancer need chemotherapy?
Nadeem Bilani • 4 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals